Austin D. Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Austin D. Williams has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Richard J. Bleicher
Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA
15 shared publicationsAllison A. Aggon
Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA
9 shared publicationsAndrea S. Porpiglia
Division of Breast Surgery, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
7 shared publicationsCecilia Chang
Research Institute, Endeavor Health, Evanston, USA
7 shared publicationsWalker Lyons
Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA
6 shared publicationsAlycia So
Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA
5 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 220 (1) , 6
National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer
Purpose: De-escalation has become standard across breast cancer management. Many early-stage HR+/HER2-negative breast cancers are eligible for both SLNB omission and accelerated partial breast irradiation (APBI). However, the oncologic safety of dual de-escalation has not been evaluated except in patients ≥ 70 years. We sought to characterize national practice patterns and factors associated with adoption of this dual de-escalation approach. Methods: Women aged 50–69 years with clinical T1–T2N0 breast cancer who underwent upfront breast-conserving surgery between (2012 − 2022) were identified from the National Cancer Database. Patients were categorized by axillary surgery and by adjuvant radiation modality (WBI, APBI, or none). We assessed trends and factors associated with de-escalation. Results: 316,324 patients met inclusion criteria, of whom 98% underwent SLNB. Among patients who underwent SLNB, 83% received WBI, 11% received APBI, and 6% received no radiation. In contrast, among patients in whom SLNB was omitted, 63% received WBI, 8% received APBI, and 30% received no radiation. SLNB omission remained low throughout the study period at < 3%, while APBI use increased from 8% to 16.5%. Dual de-escalation was rarely performed throughout the study period remaining < 0.30%. Shared predictors of de-escalation included cT1 tumors, ductal histology, low grade, and treatment at academic/research programs. Conclusion: These findings highlight the need for prospective studies to define the safety, outcomes, and patient selection criteria for combined de-escalation strategies. Until these data are available, patient-centered discussions are essential to determine the most appropriate strategy for patients with low-risk disease.
- 18 October 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 220 (1) , 6
Open AccessNational trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer
Purpose: De-escalation has become standard across breast cancer management. Many early-stage HR+/HER2-negative breast cancers are eligible for both SLNB omission and accelerated partial breast irradiation (APBI). However, the oncologic safety of dual de-escalation has not been evaluated except in patients ≥ 70 years. We sought to characterize national practice patterns and factors associated with adoption of this dual de-escalation approach. Methods: Women aged 50–69 years with clinical T1–T2N0 breast cancer who underwent upfront breast-conserving surgery between (2012 − 2022) were identified from the National Cancer Database. Patients were categorized by axillary surgery and by adjuvant radiation modality (WBI, APBI, or none). We assessed trends and factors associated with de-escalation. Results: 316,324 patients met inclusion criteria, of whom 98% underwent SLNB. Among patients who underwent SLNB, 83% received WBI, 11% received APBI, and 6% received no radiation. In contrast, among patients in whom SLNB was omitted, 63% received WBI, 8% received APBI, and 30% received no radiation. SLNB omission remained low throughout the study period at < 3%, while APBI use increased from 8% to 16.5%. Dual de-escalation was rarely performed throughout the study period remaining < 0.30%. Shared predictors of de-escalation included cT1 tumors, ductal histology, low grade, and treatment at academic/research programs. Conclusion: These findings highlight the need for prospective studies to define the safety, outcomes, and patient selection criteria for combined de-escalation strategies. Until these data are available, patient-centered discussions are essential to determine the most appropriate strategy for patients with low-risk disease.
Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection
Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high‐risk, early‐stage disease. Cyclin‐dependent kinase 4 and 6 inhibitors, initially established as a standard component of first‐line therapy in the metastatic setting based on improvements in progression‐free and overall survival, have since been evaluated in the adjuvant setting. While adjuvant palbociclib did not improve invasive disease‐free survival, the monarchE and NATALEE trials demonstrated that abemaciclib and ribociclib, respectively, reduce recurrence risk in patients with high‐risk, early‐stage disease, with emerging overall survival data further supporting their use. However, the absolute magnitude of benefit varies substantially with baseline risk, and treatment‐related toxicity and adherence challenges must be considered, as approximately 20% to 25% of patients discontinue therapy before completion. The integration of these agents into clinical practice also intersects with ongoing efforts to deescalate axillary surgery, as treatment eligibility has been largely defined by anatomic staging, particularly nodal status. Available data suggest that the incremental impact of axillary surgery on identifying candidates for cyclin‐dependent kinase 4 and 6 inhibition is modest, especially among the favorable‐risk populations now eligible for surgical deescalation. As the field evolves, advances in molecular risk stratification, genomic profiling, and dynamic biomarkers are poised to shift treatment selection from anatomic staging toward biologically driven approaches. Multidisciplinary decision‐making that integrates tumor biology, anticipated absolute benefit, toxicity, patient preferences, and surgical considerations will be essential to ensure individualized care.
Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection
Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high‐risk, early‐stage disease. Cyclin‐dependent kinase 4 and 6 inhibitors, initially established as a standard component of first‐line therapy in the metastatic setting based on improvements in progression‐free and overall survival, have since been evaluated in the adjuvant setting. While adjuvant palbociclib did not improve invasive disease‐free survival, the monarchE and NATALEE trials demonstrated that abemaciclib and ribociclib, respectively, reduce recurrence risk in patients with high‐risk, early‐stage disease, with emerging overall survival data further supporting their use. However, the absolute magnitude of benefit varies substantially with baseline risk, and treatment‐related toxicity and adherence challenges must be considered, as approximately 20% to 25% of patients discontinue therapy before completion. The integration of these agents into clinical practice also intersects with ongoing efforts to deescalate axillary surgery, as treatment eligibility has been largely defined by anatomic staging, particularly nodal status. Available data suggest that the incremental impact of axillary surgery on identifying candidates for cyclin‐dependent kinase 4 and 6 inhibition is modest, especially among the favorable‐risk populations now eligible for surgical deescalation. As the field evolves, advances in molecular risk stratification, genomic profiling, and dynamic biomarkers are poised to shift treatment selection from anatomic staging toward biologically driven approaches. Multidisciplinary decision‐making that integrates tumor biology, anticipated absolute benefit, toxicity, patient preferences, and surgical considerations will be essential to ensure individualized care.
- Open Access
- 8 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9620-9629
Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria
Introduction: Recent trials have expanded eligibility for omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer, while adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in patients with high-risk features that often rely on pathologic nodal status. The impact of SLNB omission on identifying candidates for CDK4/6 inhibitor therapy remains unclear. We evaluated how omission affects eligibility under Choosing Wisely and American Society of Clinical Oncology (ASCO) criteria. Methods: From the National Cancer Database (2018–2022), we identified women aged ≥ 50 years with hormone-receptor-positive, HER2-negative, clinical T1–2N0M0 breast cancer treated with upfront surgery and SLNB. Omission-eligible cohorts were defined based on Choosing Wisely and ASCO criteria. CDK4/6 inhibitor (abemaciclib and ribociclib) eligibility was assessed using tumor features alone (modeling omission), SLNB findings, and axillary lymph node dissection (ALND) findings. Multivariable logistic regression identified predictors of SLNB determining eligibility. Results: Among 150,629 patients, 73% met SLNB omission criteria. Positive SLNs were found in 9–10%, and only 2% had pN2–3 disease. SLNB omission would miss 4% (abemaciclib) and 8% (ribociclib) of eligible patients in the Choosing Wisely cohort, and 1 and 8%, respectively, in the ASCO cohort. ALND increased candidacy by only 1%. Approximately 13 SLNBs were required to identify one CDK4/6-eligible patient, and 299 SLNBs were required to identify one patient expected to derive a 5-year invasive disease-free survival benefit. Conclusions: SLNB omission excludes few patients eligible for adjuvant CDK4/6 inhibitor therapy. These findings support shared decision-making and suggest SLNB should not be performed solely to determine CDK4/6 eligibility.
- 8 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9620-9629
Open AccessRole of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria
Introduction: Recent trials have expanded eligibility for omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer, while adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in patients with high-risk features that often rely on pathologic nodal status. The impact of SLNB omission on identifying candidates for CDK4/6 inhibitor therapy remains unclear. We evaluated how omission affects eligibility under Choosing Wisely and American Society of Clinical Oncology (ASCO) criteria. Methods: From the National Cancer Database (2018–2022), we identified women aged ≥ 50 years with hormone-receptor-positive, HER2-negative, clinical T1–2N0M0 breast cancer treated with upfront surgery and SLNB. Omission-eligible cohorts were defined based on Choosing Wisely and ASCO criteria. CDK4/6 inhibitor (abemaciclib and ribociclib) eligibility was assessed using tumor features alone (modeling omission), SLNB findings, and axillary lymph node dissection (ALND) findings. Multivariable logistic regression identified predictors of SLNB determining eligibility. Results: Among 150,629 patients, 73% met SLNB omission criteria. Positive SLNs were found in 9–10%, and only 2% had pN2–3 disease. SLNB omission would miss 4% (abemaciclib) and 8% (ribociclib) of eligible patients in the Choosing Wisely cohort, and 1 and 8%, respectively, in the ASCO cohort. ALND increased candidacy by only 1%. Approximately 13 SLNBs were required to identify one CDK4/6-eligible patient, and 299 SLNBs were required to identify one patient expected to derive a 5-year invasive disease-free survival benefit. Conclusions: SLNB omission excludes few patients eligible for adjuvant CDK4/6 inhibitor therapy. These findings support shared decision-making and suggest SLNB should not be performed solely to determine CDK4/6 eligibility.
- Open Access
- 6 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9630-9631
ASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4/6 Inhibition
- 6 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9630-9631
Open AccessASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4/6 Inhibition
- Open Access
- 24 May 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3) , 56
Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection
Purpose: The role of axillary surgery in patients with de novo metastatic breast cancer (dnMBC) undergoing primary site surgery is unclear. We evaluated patterns of axillary management and associations with overall survival (OS) in this population. Methods: We used the National Cancer Database (2012-2020) to identify patients with dnMBC. Patients were grouped by receipt of breast surgery and axillary surgery (none, sentinel lymph node biopsy [SLNB] or axillary lymph node dissection [ALND]). Multivariable Cox proportional hazards models assessed factors associated with axillary surgery and OS. Results: Among 39,946 eligible patients, 7,808 (19.5%) underwent surgery of the primary site, of whom 79.8% underwent axillary surgery (79.5% ALND, 20.4% SLNB). Compared with no axillary surgery, those who underwent axillary surgery had more favorable clinicodemographic characteristics (younger, fewer comorbidities, lower T stage, bone-only metastases). In patients with clinically node-negative disease, 41.6% had pathologically negative nodes, with higher rates among those with HR+/HER- disease and those who did not have systemic therapy prior to surgery. On multivariable analysis, axillary surgery was independently associated with improved OS (HR 0.70; 95% CI 0.63–0.78; p<0.001). Conclusion: Among patients with dnMBC undergoing primary site surgery, axillary surgery was associated with improved survival in this retrospective analysis, though the effect is likely influenced by selection bias. Until prospective data define which subgroups may benefit, axillary surgery should be considered selectively, with SLNB preferred over ALND for patients without palpable adenopathy to minimize morbidity. Multidisciplinary evaluation remains essential to tailor surgical decisions that balance survival, function, and quality of life.
- 24 May 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3) , 56
Open AccessImpact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection
Purpose: The role of axillary surgery in patients with de novo metastatic breast cancer (dnMBC) undergoing primary site surgery is unclear. We evaluated patterns of axillary management and associations with overall survival (OS) in this population. Methods: We used the National Cancer Database (2012-2020) to identify patients with dnMBC. Patients were grouped by receipt of breast surgery and axillary surgery (none, sentinel lymph node biopsy [SLNB] or axillary lymph node dissection [ALND]). Multivariable Cox proportional hazards models assessed factors associated with axillary surgery and OS. Results: Among 39,946 eligible patients, 7,808 (19.5%) underwent surgery of the primary site, of whom 79.8% underwent axillary surgery (79.5% ALND, 20.4% SLNB). Compared with no axillary surgery, those who underwent axillary surgery had more favorable clinicodemographic characteristics (younger, fewer comorbidities, lower T stage, bone-only metastases). In patients with clinically node-negative disease, 41.6% had pathologically negative nodes, with higher rates among those with HR+/HER- disease and those who did not have systemic therapy prior to surgery. On multivariable analysis, axillary surgery was independently associated with improved OS (HR 0.70; 95% CI 0.63–0.78; p<0.001). Conclusion: Among patients with dnMBC undergoing primary site surgery, axillary surgery was associated with improved survival in this retrospective analysis, though the effect is likely influenced by selection bias. Until prospective data define which subgroups may benefit, axillary surgery should be considered selectively, with SLNB preferred over ALND for patients without palpable adenopathy to minimize morbidity. Multidisciplinary evaluation remains essential to tailor surgical decisions that balance survival, function, and quality of life.
- Open Access
- 5 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1240
ASO Visual Abstract: Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes
- 5 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1240
Open AccessASO Visual Abstract: Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes
- Open Access
- 13 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1150-1161
Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes
Background: Men are often diagnosed with node-positive breast cancer and treated with mastectomy because of a lack of screening and an unfavorable tumor-to-breast ratio. The AMAROS trial showed no difference in outcomes between axillary lymph node dissection (ALND) and axillary radiation in women with cT1-2N0 breast cancer with positive sentinel lymph nodes (+SLNs). Axillary management in men remains unstandardized, so we assessed current trends and outcomes. Methods: Males with cT1-2N0M0 breast cancer undergoing mastectomy with one to two +SLNs were identified from the National Cancer Database (2018–2021). Patients were stratified by axillary management. Postmastectomy radiotherapy (PMRT) included chest wall and axillary fields. Management strategies and overall survival were analyzed. Results: Among 445 patients, 25% had no further axillary treatment, 22% underwent ALND, 29% PMRT, and 24% ALND+PMRT. Patients with two +SLNs more often underwent ALND+PMRT (43% vs. 19%, p < 0.001). The use of PMRT rose over time (23–36%), whereas ALND alone declined (27–12%). Additional positive nodes were found in 31% of ALND cases, with no difference between ALND and ALND+PMRT. Performance of ALND delayed PMRT (194 vs. 133 days from diagnosis, p < 0.001). On multivariable analysis, two +SLNs predicted ALND+PMRT (odds ratio 2.5, p = 0.006). Older age ( p < 0.001) and two +SLNs ( p = 0.03) were linked to worse overall survival, whereas axillary management was not ( p = 0.23). Conclusion: Although axillary strategies are proven safe and effective in women, their extrapolation to men is inconsistent. Half of men undergoing mastectomy are undertreated or overtreated, underscoring the need for multidisciplinary consensus and prospective male-specific data to guide care and reduce morbidity.
- 13 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1150-1161
Open AccessAxillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes
Background: Men are often diagnosed with node-positive breast cancer and treated with mastectomy because of a lack of screening and an unfavorable tumor-to-breast ratio. The AMAROS trial showed no difference in outcomes between axillary lymph node dissection (ALND) and axillary radiation in women with cT1-2N0 breast cancer with positive sentinel lymph nodes (+SLNs). Axillary management in men remains unstandardized, so we assessed current trends and outcomes. Methods: Males with cT1-2N0M0 breast cancer undergoing mastectomy with one to two +SLNs were identified from the National Cancer Database (2018–2021). Patients were stratified by axillary management. Postmastectomy radiotherapy (PMRT) included chest wall and axillary fields. Management strategies and overall survival were analyzed. Results: Among 445 patients, 25% had no further axillary treatment, 22% underwent ALND, 29% PMRT, and 24% ALND+PMRT. Patients with two +SLNs more often underwent ALND+PMRT (43% vs. 19%, p < 0.001). The use of PMRT rose over time (23–36%), whereas ALND alone declined (27–12%). Additional positive nodes were found in 31% of ALND cases, with no difference between ALND and ALND+PMRT. Performance of ALND delayed PMRT (194 vs. 133 days from diagnosis, p < 0.001). On multivariable analysis, two +SLNs predicted ALND+PMRT (odds ratio 2.5, p = 0.006). Older age ( p < 0.001) and two +SLNs ( p = 0.03) were linked to worse overall survival, whereas axillary management was not ( p = 0.23). Conclusion: Although axillary strategies are proven safe and effective in women, their extrapolation to men is inconsistent. Half of men undergoing mastectomy are undertreated or overtreated, underscoring the need for multidisciplinary consensus and prospective male-specific data to guide care and reduce morbidity.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (7) , 1183-1186
Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy
Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy
- 1 July 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (7) , 1183-1186
Open AccessAxillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy
Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy
- Open Access
- 29 June 2025
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1
ASO Visual Abstract: Low Socioeconomic Status at the Patient and Institutional Level Impact Achievement of Breast Cancer Quality Standards
- 29 June 2025
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1
Open AccessASO Visual Abstract: Low Socioeconomic Status at the Patient and Institutional Level Impact Achievement of Breast Cancer Quality Standards